EFFECTS OF 11-WEEK INCREASE IN DIETARY EICOSAPENTAENOIC ACID ON BLEEDING TIME, LIPIDS, AND PLATELET AGGREGATION

doi:10.1016/S0140-6736(81)91436-7

The Lancet

Volume 318, Issue 8257, 28 November 1981, Pages 1190-1193

https://doi.org/10.1016/S0140-6736(81)91436-7 Get rights and content

Abstract

The effect of a diet rich in eicosapentaenoic acid (EPA) on platelet phospholipid fatty acid composition, platelet aggregation, and bleeding time was studied in 10 healthy men, whose usual diet was partly replaced by fish for 11 weeks. This diet provided 2-3 g EPA per day. Two doses (3. 5 and 10 mg/kg body-weight) of acetylsalicylic acid (ASA) were given before and during the diet. The fish diet prolonged bleeding time (by 42%) and decreased platelet aggregability. The changes in platelet phospholipid fatty acid composition consisted of increases in the ω-3 series (C20:5 and C22:6) and decreases in the ω-6 series (C18:2 and C20:3). The reduction in platelet aggregation induced by collagen and ADP did not parallel the changes in platelet membrane phospholipids and bleeding times. Diminished platelet aggregation induced by collagen lasted only 3 weeks (while subject was still on the diet), whereas the decreased sensitivity to ADP persisted for at least 11 weeks after the volunteers had resumed their normal diet. ASA taken before the diet prolonged bleeding time by as much as did the diet itself. ASA taken during the diet prolonged bleeding time by more than the sum of the increases in bleeding time caused by ASA and by the EPA diet separately, but the synergism was not significantly more than additive. The findings suggest that a diet rich in ω-3 polyunsatured fatty acids reduces the interaction between platelets and the vessel wall by mechanisms which are more complex than just a reduction in susceptibility of platelets to the naturally occurring agents collagen and ADP, or an imbalance between proaggregatory and anti-aggregatory prostaglandin derivatives.

References (20)

J. Dyerberg et al.
Fatty acid composition of the plasma lipids in Greenland Eskimos
Am J Clin Nutr
(1975)
J. Dyerberg et al.
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis
Lancet
(1978)
J. Dyerberg et al.
Haemostatic function and platelet polyunsaturated fatty acids in in Eskimos
Lancet
(1979)
W. Siess et al.
Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet
Lancet
(1980)
Cl Schneider
Rapid estimation of plasma fibrinogen concentration and its use as a guide to therapy
Am J Obstet Gynecol
(1952)
A. Berthelsen
Gronlands medicinsk statistik og Nosografi. iIII Det saedvanlige gronlandske sygdomsbillede
Meddelelser om Gr $o ̸$ nland, haefte
(1940)
N. Kronmann et al.
Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-74
Acta Med Scand
(1980)
Ho Bang et al.
Plasma lipids and lipoproteins in Greenlandic west coast Eskimos
Acta Med Scand
(1972)
Ho Bang et al.
The composition of food consumed by Greenland Eskimos
Acta Med Scand
(1976)

There are more references available in the full text version of this article.

Cited by (244)

Platelet dysfunction reversal with cold-stored vs room temperature–stored platelet transfusions
2024, Blood
Platelets are stored at room temperature for 5-7 days (RSP). Due to frequent and severe shortages, the FDA recently approved up to 14-day cold-stored platelets in plasma (CSP). However, the post-transfusion function of CSP is unknown and it is unclear which donors are best suited to provide either RSP or CSP. In this study, we sought to evaluate the post-transfusion platelet function and its predictors for platelets stored for the maximum approved storage times (7-day RSP, 14-day CSP) in healthy volunteers on acetylsalicylic acid (ASA). We conducted a randomized cross-over study in ten healthy humans. Subjects donated one platelet unit stored at either 22 °C or 4 °C based on randomization. Before transfusion, subjects ingested ASA to inhibit endogenous platelets. Transfusion recipients were tested for platelet function and lipid mediators. Platelet units were tested for lipid mediators only. A second round of transfusion with the alternative product was followed by an identical testing sequence. RSP reversed platelet inhibition significantly better in α_IIbβ₃ integrin activation-dependent assays. In contrast, CSP in recipients led to significantly more thrombin generation, which was independent of platelet microparticles. Lysophosphatidylcholine-O species levels predicted the procoagulant capacity of CSP. In contrast, polyunsaturated fatty acid concentrations predicted the aggregation response of RSP. In summary, we provide the first efficacy data of extended-stored CSP in plasma. Our results suggest that identifying ideal RSP and CSP donors is possible and pave the way for larger studies in the future. Registration: NCT03787927
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis
2023, Pharmacology and Therapeutics
Platelets are small, anucleate cells in the blood that play a crucial role in the hemostatic response but are also implicated in the pathophysiology of cardiovascular disease. It is widely appreciated that polyunsaturated fatty acids (PUFAs) play an integral role in the function and regulation of platelets. PUFAs are substrates for oxygenase enzymes cyclooxygenase-1 (COX-1), 5-lipoxygenase (5-LOX), 12-lipoxygenase (12-LOX) and 15-lipoxygenase (15-LOX). These enzymes generate oxidized lipids (oxylipins) that exhibit either pro- or anti-thrombotic effects. Although the effects of certain oxylipins, such as thromboxanes and prostaglandins, have been studied for decades, only one oxylipin has been therapeutically targeted to treat cardiovascular disease. In addition to the well-known oxylipins, newer oxylipins that demonstrate activity in the platelet have been discovered, further highlighting the expansive list of bioactive lipids that can be used to develop novel therapeutics. This review outlines the known oxylipins, their activity in the platelet, and current therapeutics that target oxylipin signaling.
Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids
2018, Prostaglandins and Other Lipid Mediators
Citation Excerpt :
Several interventional studies were reviewed by Begg et al. and largely concluded that ω-3 PUFAs may provide a clinical benefit, but the degree and nature of ω-3 PUFA cardioprotection remains unclear [89]. Thrombosis, like many of the other endpoints examined in ω-3 PUFA-oriented clinical trials, also shows mixed results [86,90–93]. Although supplementation of ω-3 PUFAs has been shown to reduce platelet aggregation and activation in healthy subjects, a higher than recommended dose of ω-3 PUFAs may be needed due to platelet hyperactivite prothrombotic conditions such as in CVD.
Thrombosis is the most common underlying pathology responsible for morbidity and mortality in cardiovascular disease (CVD). Platelet adhesion, activation, and aggregation play central roles in hemostasis; however, the same process may also cause thrombosis and vessel occlusion at the site of ruptured atherosclerotic lesions leading to heart attack and stroke. ω-3 and ω-6 polyunsaturated fatty acids (PUFAs) are an essential component of the platelet phospholipid membrane and play a major role in many aspects of platelet function. Dietary supplementation of ω-3 and ω-6 PUFAs has long been used to slow the progression of CVD and to prevent acute cardiovascular events. Despite this, the role of ω-3 and ω-6 PUFAs and their oxylipin metabolites in platelet function remains controversial due to the lack in our understanding of the mechanistic regulation controlling platelet reactivity in vitro and substantial evidence for PUFA regulation of thrombotic events in vivo. In this review, we will outline the role of platelet physiology in hemostasis and the effect of ω-3 and ω-6 PUFAs on platelet function, with special emphasis on in vivo effects on hemostasis and thrombosis due to the role of PUFAs and their bioactive lipids in circulation. Further, recent mechanistic insights and evidence for cardio-protective effects of PUFAs and their bioactive lipids will be discussed.
New Lipid Strategies to Prevent/Treat Neonatal Cholestasis
2018, Gastroenterology and Nutrition: Neonatology Questions and Controversies
A growing amount of evidence suggests that specific components of parenteral nutrition (PN) are involved in the pathogenesis of intestinal failure-associated liver disease (IFALD). For a number of reasons, intravenous lipid emulsions (ILEs) are thought to play a key role in IFALD. PN without the provision of any fat source results in a higher incidence of liver dysfunction compared with PN with fat, making it difficult to draw a correlation between the role of ILE and PN-associated liver disease (PNALD) as both its presence and absence can predispose patients to developing PNALD. Moreover, excessive lipid provision is also thought to increase the incidence of IFALD. This may, in part, be caused by the widespread use of soybean oil-derived ILEs. Soybean oil-based ILEs contain high levels of proinflammatory omega-6 poly unsaturated fatty acids that result in increased production of proinflammatory products that can cause liver damage. Other components present in soybean oil-based ILEs, such as phytosterols and vitamin E content, may also contribute to the risk of IFALD. Alternative ILEs, containing fish, olive, or coconut oils, are being used to prevent or treat this potentially fatal disease. This chapter will address how the inflammatory characteristics of each oil source, the dose, and amount of phytosterols and alpha-tocopherol can either predispose patients to IFALD or be used in its prevention or treatment.
Risk of post-procedural bleeding in children on intravenous fish oil
2017, American Journal of Surgery
Intestinal failure-associated liver disease (IFALD) can be treated with parenteral fish oil (FO) monotherapy, but practitioners have raised concerns about a potential bleeding risk. This study aims to describe the incidence of clinically significant post-procedural bleeding (CSPPB) in children receiving FO monotherapy.
A retrospective chart review was performed on patients at our institution treated with intravenous FO for IFALD. CSPPB was defined as bleeding leading to re-operation, transfer to the intensive care unit, re-admission, or death, up to one month after any invasive procedure.
From 244 patients reviewed, 183 underwent ≥1 invasive procedure(s) (n = 732). Five (0.68%, 95% CI 0.22–1.59%) procedures resulted in CSPPB. FO therapy was never interrupted. No deaths due to bleeding occurred.
Findings suggest that FO therapy is safe, with a CSPPB risk no greater than that reported in the general population. O3FA should not be held in preparation for procedures or in the event of bleeding.
Reduction of prothrombin and Factor V levels following supplementation with omega-3 fatty acids is sex dependent: A randomised controlled study
2014, Journal of Nutritional Biochemistry
LCn-3PUFA comprised of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) offer cardioprotection involving a decrease in coagulant activity; however, the evidence is equivocal. We have previously demonstrated that the acute (24 h) effects and chronic (4 weeks) effects of LCn-3PUFA supplementation on platelet aggregation in human subjects are sex specific. This study investigated the mechanisms of the sex-dependent effects of LCn-3PUFA with 4 weeks supplementation of EPA-rich vs. DHA-rich oils on procoagulant and platelet activity in healthy subjects.
A double-blinded, placebo-controlled randomised trial was conducted in 94 healthy adults: male (n=41) and female (n=53). Platelet coagulation parameters including factors I, II, V, VII, VIII, IX, X, vWF:Ag and endogenous thrombin potential were measured at baseline and 4 weeks postsupplementation with EPA-rich or DHA-rich oil capsules.
We have previously reported that platelet aggregation is specifically reduced by supplementation with EPA in males and DHA in females. This sex-specific effect was also observed for decreases in plasma levels of Factor II (−7.9±3.8%, P=.026), Factor V (−6.5±4.5%, P=.022) and vWF:Ag (−7.3±2.1%, P=.034) and was most pronounced in males supplemented with EPA. In contrast, DHA-mediated reduction in platelet aggregation in females was not accompanied by any significant changes in the coagulation parameters tested.
Significant interactions between sex and specific LCn-3PUFA exist to reduce procoagulant activity differentially in males vs. females and could have profound effects on managing risk of thrombotic disease.

View all citing articles on Scopus

View full text

EFFECTS OF 11-WEEK INCREASE IN DIETARY EICOSAPENTAENOIC ACID ON BLEEDING TIME, LIPIDS, AND PLATELET AGGREGATION

Abstract

Am J Clin Nutr

Lancet

Lancet

Lancet

Am J Obstet Gynecol

Gronlands medicinsk statistik og Nosografi. iIII Det saedvanlige gronlandske sygdomsbillede

Meddelelser om Gro̸nland, haefte

Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-74

Acta Med Scand

Plasma lipids and lipoproteins in Greenlandic west coast Eskimos

Acta Med Scand

The composition of food consumed by Greenland Eskimos

Acta Med Scand

Meddelelser om Gr $o ̸$ nland, haefte